List of Excipients in Branded Drug TORSEMIDE

Generic Drugs Containing TORSEMIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	torsemide	0054-0077	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	torsemide	0054-0077	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	torsemide	0054-0077	CROSPOVIDONE
Hikma Pharmaceuticals USA Inc	torsemide	0054-0077	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	torsemide	0054-0077	POVIDONE
American Regent Inc	torsemide	0517-0771	POLYETHYLENE GLYCOL 400

What are the Most Frequently-Used Excipients in TORSEMIDE?

# Of NDCs	Excipient
8	ANHYDROUS LACTOSE
37	CELLULOSE, MICROCRYSTALLINE
37	CROSPOVIDONE
37	LACTOSE MONOHYDRATE
43	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL 400

Torsemide Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Torsemide is a mature loop diuretic with limited active-ingredient patent protection and intense tablet competition. The strongest commercial opportunities are differentiated oral delivery systems, not conventional immediate-release tablets. Formulation developers should focus on dissolution control, dose flexibility, taste masking, stability, manufacturability, and adherence in chronic heart-failure populations.

The most commercially relevant platforms are:

• Low-cost, robust immediate-release tablets
• Oral solutions and suspensions for pediatric, geriatric, and dysphagic patients
• Orally disintegrating tablets for adherence and administration without water
• Modified-release products that reduce abrupt diuresis
• Combination products with antihypertensive or heart-failure therapies
• Hospital-ready intravenous products with improved container and stability performance

What is torsemide and how is it used?

Torsemide is an anthranilic acid loop diuretic used for edema associated with congestive heart failure, renal disease, and hepatic disease. It is also indicated for hypertension in the United States. The branded products Demadex and Soaanz contain torsemide in oral tablet form, while generic products are available in multiple strengths. FDA labeling describes oral torsemide tablets as 5 mg, 10 mg, 20 mg, and 100 mg products, depending on the manufacturer and product line. [1,2]

Torsemide has a longer duration of action than furosemide in many clinical settings and has relatively high oral bioavailability. Its commercial value comes from chronic-use volume rather than exclusivity pricing.

Attribute	Torsemide
Pharmacologic class	Loop diuretic
Main indications	Heart-failure edema, renal edema, hepatic edema, hypertension
Common dosage forms	Immediate-release tablets; injectable products in selected markets
Typical strengths	5 mg, 10 mg, 20 mg, 100 mg
Administration	Oral; parenteral products where approved
Regulatory pathway	Small-molecule NDA and ANDA products
Biosimilar exposure	None
Core commercial issue	Commodity generic competition and adherence

What excipient properties matter most in torsemide formulations?

Torsemide formulation design is driven by dose uniformity, dissolution behavior, tablet robustness, and exposure to moisture. The drug is a weakly acidic compound with pH-dependent solubility. Excipients must support rapid and reproducible release across the gastrointestinal pH range without creating excessive sensitivity to manufacturing conditions.

Immediate-release tablets

The commercial baseline is a compressed immediate-release tablet. A practical formulation typically uses:

• A diluent such as microcrystalline cellulose, lactose, mannitol, or dibasic calcium phosphate
• A superdisintegrant such as crospovidone, croscarmellose sodium, or sodium starch glycolate
• A binder such as povidone or hydroxypropyl cellulose
• A lubricant such as magnesium stearate or sodium stearyl fumarate
• A glidant such as colloidal silicon dioxide
• A film coat based on hypromellose, polyvinyl alcohol, polyethylene glycol, and pigment

The primary development risk is over-lubrication. Excess magnesium stearate or prolonged blending can reduce wetting and slow dissolution. A high-disintegrant, low-hydrophobicity design is generally more attractive for low-dose strengths, where content uniformity and rapid release are critical.

Solubilization and wetting

Torsemide does not require the same solubilization technology as a highly insoluble oncology compound, but dissolution performance can still vary with particle size, polymorphic form, compression force, and excipient selection.

Potential approaches include:

• Micronized active pharmaceutical ingredient
• Spray-dried dispersions
• Wetting agents such as poloxamers or sodium lauryl sulfate
• Hydrophilic carriers such as povidone or copovidone
• Amorphous solid dispersions
• Co-processed excipient systems

These approaches are most relevant to oral liquids, orally disintegrating tablets, and low-dose products where dissolution variability affects bioequivalence risk. For a conventional generic tablet, complex solubilization may increase cost without producing a meaningful clinical or regulatory advantage.

Moisture control

Moisture management is commercially important because tablet hardness, disintegration, assay, and dissolution can change during storage. Developers should evaluate:

• Low-moisture excipient grades
• Desiccant-backed bottles
• High-barrier blister films
• Film-coating moisture protection
• Water activity during granulation
• Compatibility between torsemide and reducing sugars

Direct compression can reduce water exposure and simplify manufacturing. Where wet granulation is needed for content uniformity, the process should be designed around controlled residual moisture rather than maximum granule density.

What formulations are protected or commercially differentiated?

The conventional torsemide tablet has limited differentiation. The commercial opportunity lies in dosage forms that solve a patient or payer problem.

Oral liquids

An oral solution or suspension can address patients who cannot swallow tablets, including older adults, patients with advanced heart failure, and pediatric populations. Key excipient issues include:

• pH adjustment for solubility
• Buffer capacity
• Preservative effectiveness
• Palatability and bitterness
• Sedimentation control for suspensions
• Container adsorption
• Dose-measuring accuracy

A true solution has a better user experience than a suspension but may require pH modification, cosolvents, surfactants, or complexation. A suspension can reduce formulation complexity but creates redispersibility and dose-uniformity requirements.

Taste masking is a major commercial barrier. Torsemide oral liquids should be screened with flavor systems, sweeteners, ion-exchange resins, polymeric coatings, or lipid-based masking systems. Pediatric commercialization would require a separate palatability and dosing strategy rather than simple conversion of an adult tablet.

Orally disintegrating tablets

An orally disintegrating tablet could support patients with dysphagia and reduce dependence on water. Suitable excipient systems include mannitol-based fillers, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking polymers.

The main risks are:

• Torsemide bitterness
• Fragility during packaging and transport
• Moisture sensitivity
• Dose uniformity at low strengths
• In-mouth grittiness
• Slower disintegration from excessive lubricant

Unit-dose blister packaging is likely preferable to multidose bottles where product integrity and portability are central to the value proposition.

Modified-release formulations

A modified-release torsemide product could target patients who experience inconvenient or abrupt diuresis after dosing. The technical challenge is pharmacologic: excessive release prolongation or dose dumping could create under-diuresis followed by delayed fluid loss.

Potential technologies include:

• Hydrophilic matrix tablets using hypromellose
• Multiparticulate capsules
• Coated pellets
• Osmotic systems
• Pulsatile-release systems

A modified-release product would require strong clinical positioning. A formulation patent alone may not create durable value unless the product demonstrates improved adherence, reduced nocturia, more consistent fluid management, or a clinically meaningful reduction in adverse events.

How strong is the torsemide patent estate?

The core torsemide molecule and conventional immediate-release tablet technology are mature. Original composition and basic product protection have expired or are no longer the principal barrier to generic entry. The relevant intellectual-property value is concentrated in later-developed dosage forms, manufacturing processes, delivery technologies, and specific combinations.

Patent category	Commercial relevance
Original torsemide compound claims	Low; mature and generally expired
Conventional immediate-release tablet	Low; readily reproducible by generic manufacturers
Oral liquid formulation	Moderate if claims cover pH, stability, taste masking, or preservative systems
Orally disintegrating tablet	Moderate if claims cover rapid disintegration and palatability
Modified-release formulation	Potentially high if supported by clinical differentiation
Combination product	Moderate, depending on active ingredients and indication
Manufacturing process	Moderate if it improves purity, polymorph control, yield, or cost
Packaging and stability	Usually narrow but commercially useful

A formulation patent is stronger when it claims a defined composition and measurable performance, such as dissolution, stability, particle-size distribution, or pharmacokinetic behavior. Broad claims covering routine excipient substitutions are more vulnerable to obviousness and enablement challenges.

When does torsemide lose exclusivity?

Torsemide has already lost primary small-molecule exclusivity in the United States. Generic manufacturers have marketed torsemide tablets for years, and the market is supplied through ANDA pathways rather than protected by an active new-molecular-entity exclusivity period.

The relevant exclusivity distinction is between:

1. The active ingredient, which is genericized.
2. A particular branded formulation, such as a later-approved dosage form.
3. A method of use or formulation patent that may delay a specific product but does not restore molecule-wide exclusivity.

A later 505(b)(2) product can obtain product-specific patents or three-year exclusivity for a new clinical investigation, but that protection does not prevent ordinary generic torsemide tablets from remaining on the market. [3]

What is the FDA and Orange Book status of torsemide?

FDA-approved torsemide products include generic tablets and branded products. The Orange Book identifies approved drug products, reference listed drugs, patent information, and exclusivity where applicable. Conventional torsemide tablets are generally subject to ANDA competition. [4]

The regulatory strategy depends on the product:

• A conventional tablet generally uses an ANDA referencing the applicable reference listed drug.
• A new oral liquid, modified-release product, or other differentiated dosage form may require a 505(b)(2) NDA.
• A product with a new indication, dosing regimen, or clinical benefit may need additional clinical evidence.
• An injectable product requires parenteral quality controls, sterility assurance, particulate control, and container-closure validation.

A formulation change does not automatically create regulatory exclusivity. The sponsor must establish a distinct regulatory basis and satisfy any applicable clinical, pharmacokinetic, or bioequivalence requirements.

Which companies are challenging torsemide exclusivity?

The principal competitive pressure comes from generic manufacturers, including companies that market torsemide tablets through ANDA approvals. Because the core product is mature, competition is more likely to involve abbreviated applications, contract manufacturing, private-label supply, and price-based tenders than high-profile Paragraph IV litigation.

What is the Paragraph IV risk?

Paragraph IV risk is most relevant to a later torsemide formulation with live Orange Book-listed patents. A generic applicant could challenge claims covering:

• Modified-release profiles
• Specific excipient ratios
• Particle-size distributions
• Oral-liquid stability
• Taste-masking systems
• Combination products
• New dosing regimens

For conventional immediate-release tablets, the commercial threat is usually ordinary generic substitution rather than a new Paragraph IV event. Litigation risk rises when a branded formulation carries meaningful reimbursement or when a patent blocks a high-value delivery platform.

What generic launch scenarios exist for torsemide?

Three launch scenarios dominate.

Conventional generic entry

This is the base case. Multiple manufacturers supply immediate-release tablets, pricing declines, and differentiation depends on manufacturing cost, supply reliability, and wholesaler access.

Authorized or branded-generic positioning

A manufacturer can use packaging, dose availability, shortage resilience, or specialty-pharmacy distribution to obtain modest commercial differentiation. The product remains pharmacologically interchangeable but may compete on service and supply.

Reformulated product launch

A 505(b)(2) formulation can pursue a premium if it provides a measurable advantage. The strongest candidates are an oral liquid, an orally disintegrating tablet, or a modified-release product. The main risk is that prescribers and payers may view the product as substitutable with inexpensive tablets.

How does torsemide compare with furosemide?

Torsemide competes primarily with furosemide, bumetanide, and other loop diuretics. Furosemide has a larger historical market and broader low-cost availability. Torsemide can support differentiated positioning through predictable oral absorption, longer duration, tablet convenience, and heart-failure adherence programs.

Factor	Torsemide	Furosemide
Generic maturity	High	Very high
Oral absorption	Generally more predictable	More variable
Dosage-form opportunity	Liquid, ODT, modified release	Similar, but larger competitive field
Price pressure	High	Very high
Clinical differentiation	Possible in selected heart-failure strategies	Strong incumbent position
Commercial barrier	Low-cost substitution	Established prescribing habits

The formulation opportunity is stronger when the product addresses administration or adherence rather than claiming a broad clinical superiority unsupported by comparative evidence.

What licensing deals and commercial partnerships are relevant?

Torsemide has no widely recognized current licensing structure comparable to a newly launched specialty drug. Commercial opportunities are more likely to involve:

• Co-development of a 505(b)(2) formulation
• Contract manufacturing of tablets or liquids
• Private-label distribution
• Regional licensing of differentiated dosage forms
• Hospital supply agreements
• Combination-product partnerships
• Technology licensing for taste masking or modified release

The most defensible deal asset is a formulation with regulatory readiness, validated manufacturing, and a clear reimbursement rationale. A composition patent without clinical or commercial differentiation is less attractive to licensors.

What manufacturing and geographic barriers exist?

Manufacturing barriers are modest for conventional tablets but higher for specialized presentations.

United States

The United States has a mature generic market, FDA-approved reference products, and strong substitution pressure. A formulation sponsor must manage ANDA or 505(b)(2) requirements, cGMP compliance, bioequivalence, stability, and Orange Book patent strategy.

Europe

European commercialization depends on national pricing, decentralized or centralized regulatory pathways, and tender dynamics. A low-cost tablet has limited pricing power. A liquid or adherence-oriented product may gain value in selected hospital or home-care channels.

Emerging markets

Demand may be supported by heart-failure prevalence, renal disease, and low-cost access programs. Local manufacturing, registration requirements, and supply reliability can be more important than patent protection. Heat and humidity stability should be evaluated early for markets using bottles or non-barrier packaging.

What is the revenue exposure for torsemide manufacturers?

Revenue exposure is usually modest on a molecule-wide basis because torsemide is generic. Exposure can still be material for companies with:

• Large institutional contracts
• High-volume generic portfolios
• Branded specialty formulations
• Hospital injectable supply
• Private-label distribution
• Broad cardiovascular product bundles

Public company filings generally do not isolate torsemide revenue. Commercial analysis should therefore focus on product-level market share, formulary placement, supply contracts, dosage-form mix, and gross-margin structure rather than reported corporate revenue.

Key Takeaways

• Torsemide is a mature generic loop diuretic with limited molecule-level exclusivity.
• Conventional immediate-release tablets are difficult to differentiate and face strong price competition.
• The best excipient opportunities are oral liquids, orally disintegrating tablets, and carefully designed modified-release systems.
• Superdisintegrants, wetting agents, low-moisture excipients, taste-masking polymers, and protective packaging are central formulation tools.
• A 505(b)(2) strategy may be appropriate for a differentiated dosage form, but regulatory exclusivity does not prevent generic tablet competition.
• Patent value is concentrated in specific formulation, manufacturing, combination, and method-of-use claims.
• Commercial success depends on adherence, administration, supply reliability, and reimbursement rather than active-ingredient novelty.
• Torsemide has no biosimilar risk because it is a chemically synthesized small molecule.
• Furosemide remains the principal competitive benchmark and creates a high price ceiling for any new torsemide product.
• The strongest licensing asset is a validated formulation with clinical positioning and a credible payer strategy.

FAQs

Can torsemide be formulated as an oral solution?

Yes. An oral solution requires control of pH-dependent solubility, taste, preservative performance, container compatibility, and dose-measuring accuracy. A suspension may be easier to develop but must meet redispersibility and dose-uniformity requirements.

Is torsemide suitable for an orally disintegrating tablet?

Yes. An orally disintegrating tablet could address dysphagia and water-free administration. Taste masking, moisture protection, mechanical strength, and rapid disintegration are the primary development issues.

Does torsemide have biosimilar competition?

No. Torsemide is a small-molecule chemical drug. Competition occurs through generic ANDA products, not biosimilar applications.

Can an excipient combination create torsemide market exclusivity?

An excipient combination can support formulation patent claims, but it does not automatically create exclusivity. The claims must be novel, non-obvious, enabled, and linked to a distinct regulatory product.

Is a modified-release torsemide product commercially attractive?

It can be attractive if it reduces dosing inconvenience, improves adherence, or produces a clinically meaningful diuretic profile. Without demonstrated patient or payer value, low-cost immediate-release tablets will constrain pricing.

References

1. U.S. Food and Drug Administration. (2010). Demadex (torsemide) tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (2017). Soaanz (torsemide) tablets prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023). 505(b)(2) applications. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.